Publikationen in Zusammenarbeit mit Forschern von Kyoto University (46)

2024

  1. Correction to: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

  3. Country-level gender inequality is associated with structural differences in the brains of women and men

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 20

  4. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

2022

  1. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  2. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Optical coherence tomography in coronary atherosclerosis assessment and intervention

    Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703

  5. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 738-751

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  3. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

  4. Spontaneous ARIA-like events in cerebral amyloid angiopathy–related inflammation a multicenter prospective longitudinal cohort study

    Neurology, Vol. 97, Núm. 18, pp. E1809-E1822

  5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  3. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

    Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354

  4. β-Catenin Role in the Vulnerability/Resilience to Stress-Related Disorders Is Associated to Changes in the Serotonergic System

    Molecular Neurobiology, Vol. 57, Núm. 3, pp. 1704-1715

2019

  1. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)

    BMC Cancer